Gastroenterhepatology
Clinical Trials Experience in Indonesia
Equilab's experience in oncology trials in patients includes a range of indications, but is not limited to:
-
Hepatitis
-
Chronic liver disease
-
Non Alcoholic Fatty Liver Disease (NAFLD)
-
Gastroesophageal Reflux Disease (GERD)
-
Gut microbiome
Let's collaborate together with Equilab for your clinical trial!
Our Clinical Trial Experiences in Numbers
20+
Sites involved in the study.
700+
Patients enrolled.
Phase 1-3
Types study phase we have experience.
As Your CRO, We Provide End-to-End Services for Your Gastroenterhepatology Trials
Our services are well-planned to align with your study's specific requirements, which includes but not limited to:
-
Vast Site and Network of Principal Investigators
Our extensive network of PIs and clinical sites across Indonesia provides unparalleled access to a large, diverse patient population. The high availability of existing treatment makes recruitment for gastrointestinal clinical trials challenging. But we have a proven track record of recruiting up to 100 patients within a single month, helping you meet enrollment goals and accelerate your trial.
-
Data Management and Statistical Analysis
We are skilled at handling the complex data common in these trials, from patient-reported outcomes to biomarkers. Our biostatistician team provides comprehensive analysis to transform your data into a reliable clinical study report.
-
Clinical Monitoring
Our CRAs ensure that all trial activities adhere to the highest standards of Good Clinical Practice (GCP). Through on-site or remote monitoring, we safeguard patient safety, maintain data integrity, and ensure full regulatory compliance.
Overview
The Rising Burden of Gastrointestinal and Liver Diseases in Indonesia.
Indonesia faces a dual health challenge, grappling with both a significant burden of infectious diseases and a rising trend of non-infectious conditions in gastroenterology and hepatology. While infectious diseases remain prevalent, the country is witnessing a dramatic increase in chronic conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) and Gastroesophageal Reflux Disease (GERD), driven by changing lifestyles and diet.
With experiences in conducting the clinical trials for this therapeutic area, Equilab is at the forefront of tackling this growing disease burden. We have managed clinical trials for a wide range of conditions, including hepatitis, NAFLD, and the human microbiome, leveraging our vast network of expert investigators and Key Opinion Leaders (KOLs) to deliver high-quality clinical research that contributes to developing innovative treatments for patients in Indonesia.